Archive · 5 Jun 2025
SPARC Shares Plunge Following SCD-044 Drug Trial Failure
A medicine called SCD-044, meant to help with skin problems like psoriasis and eczema, didn't work as well as hoped in tests.
The tests were run by a company called SPARC.
The drug was supposed to improve skin problems, but it did not reach its goals in the studies.
Because of this, they are stopping the research on the drug and will decide what to do next.
This news caused the company's stock to drop in value.
SPARC shares fell 18% after trial results.
The drug, SCD-044, failed to meet primary endpoints.
Trials tested SCD-044 for psoriasis and atopic dermatitis.
Development of SCD-044 will be discontinued.
The drug was considered a key asset in the specialty pipeline.
- Who
- Sun Pharma Advanced Research Company (SPARC).
- What
- SPARC's shares fell after disappointing results of SCD-044 drug trials.
- When
- Announced on June 4.
- Where
- Trials for psoriasis and atopic dermatitis.
- Why
- SCD-044 failed to meet primary endpoints in trials.
- Drug Name
- SCD-044 (Vibozilimod)
- Targeted Conditions
- Psoriasis and Atopic Dermatitis
- Company Affected
- SPARC (Sun Pharma)
- Share Drop
- 18%
- Trial Phase
- Phase 2
- Next Steps
- Assessment of compound
